Sponsor Overview
Explore verified public information about Genentech, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Expanded Access Programs allow a limited group of patients, who meet specific criteria, to have access to a specific investigational medicine. EAPs are studies managed by the company and follow a specific protocol, which is developed in consultation with the FDA.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 9 supporting sources.
Conditions: Muscular Atrophy, Spinal
Conditions: Non-Small Cell Lung Cancer
Conditions: HER2-positive Breast Cancer
Conditions: Basal Cell Carcinoma
Conditions: Urothelial Carcinoma
Conditions: Idiopathic Pulmonary Fibrosis
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria https://www.gene.com/patients/clinical-trial-information/other-types-of-access#general-criteria
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.